Press Releases

  • 03 Oct 2013
    - Press Release

    Small and Medium Sized Biopharmaceutical Companies endorse further clinical data sharing but concerned about implementation as proposed.

    European Biopharmaceutical Enterprises, EBE, a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA, recognises the potential for scientific and public health benefits of providing greater access to information from clinical trials. Majority of EBE members are small and medium sized biopharmaceutical companies they share EFPIA’s concerns of which could put at risk the promotion of public health, both in Europe and internationally: risks of de-identification of patient data, sharing of companies’ commercially confidential information, and commercial consequences of secondary analysis of data for approved products. 

    Read more | Download Document (163.04 kB)
  • 10 Jul 2013
    - Press Release

    IMI2 Launch to Further Innovative Medicines Initiative Success

    The European Biopharmaceutical Enterprises – EBE - a specialised group of EFPIA - the European Federation of Pharmaceutical Industries and Associations, is pleased to announce the European Commission launch of the IMI2 research funding initiative, which will build upon the success of the Innovative Medicines Initiative in a continued effort to bring innovative solutions to patients.

    Read more | Download Document (234.81 kB)
  • 08 May 2013
    - Press Release

    MOCA Report a welcome stepping stone, but access to orphan medicinal products remains unfinished business

    EuropaBio, EFPIA and EBE welcome the final report of the Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMPs) which was endorsed by the Steering Group of the Process on Corporate Responsibility in the field of Pharmaceuticals, and published on 6 May 2013 by the European Commission.

    Read more | Download Document (431.11 kB)
  • 19 Apr 2013
    - Press Release

    EFPIA, EBE and EuropaBio welcome European Commission Consensus Information Document on biosimilars in the European pharmaceutical environment

    The European Federation of Pharmaceutical Industries & Associations (EFPIA), its specialised group the European Biopharmaceutical Enterprises (EBE) and the European Association for Bioindustries (EuropaBio) welcome the consensus information document on biosimilars that was approved by the European Commission Steering Group on Access to Medicines in Europe on 17th April. The Commission will present the document at the BIO international Convention in Chicago on 23rd April. The document discusses the specifics around biosimilar medicinal products, the requirements for their marketing authorization in the EU, their market performance, and the necessary conditions within the EU pharmaceutical market to ensure there is informed and adequate use of these medicines.
    Read more | Download Document (420.97 kB)